BLOGSCAN - More Detailed Allegations About Intimidating an Avandia Whistle-Blower

On PharmaLot, this post adds some detail to previous allegations (which we most recently discussed here), that top executives, now including the top-most executive at GlaxoSmithKline tried to silence an academic physician who had doubts about the safety of rosiglitazone (Avandia). This is another reminder of the lack of transparency of the pseudo-market in pharmaceuticals. As we have said before, of course, intimidating people who blow the whistle about drug safety concerns is bad not only for the whistle-blowers, but for patients and doctors whose decisions about which treatments to give ought to be based on critical review of the best possible clinical evidence, not evidence that is filtered by secrecy and intimidation to only reflect vested interests of the makers of the treatments.

Related Post:

Widget by [ Iptek-4u ]